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ABSTRACT
We retrospectively analyzed 83 consecutive recipients of donor lymphocyte infusions (DLI) after allogeneic
transplantation for factors associated with disease response and graft-versus-host disease (GVHD). DLI was
highly effective in relapsed chronic phase chronic myeloid leukemia (CML), with 71% of patients achieving
durable complete remissions (CR). In relapsed acute myeloid leukemia, DLI led to durable CRs in 31% of
patients; the rate was <20% in all other diseases. Achieving full donor chimerism and GVHD were predictive
of CR. Grade II or higher acute or chronic GVHD occurred in 36 (43%) patients and contributed to death in
13 (16%). Even more patients, 33 (40%), died of their underlying malignancy, including 10 who developed
active GVHD. In relapsed CML, most durable CRs occurred without clinically apparent GVHD, yet all
responders achieved full donor chimerism, including 6 with coincident normal host hematopoiesis at the time
of DLI. Thus, in CML, potent lymphohematopoietic graft-versus-host reactions occurred even in the absence
of clinically apparent GVHD; this confirms the ability to dissociate these processes and argues against a
leukemia-specific immunologic effect. DLI clearly has efficacy in the treatment of relapsed disease after
allogeneic transplantation. However, with the exception of CML, most patients die of their underlying disease
because of insufficient antitumor activity even with active GVHD.
© 2006 American Society for Blood and Marrow Transplantation
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HNTRODUCTION
Allogeneic blood or marrow transplantation
alloBMT) has the potential to produce long-term
isease-free survival and even cures in some patients
ith hematologic malignancies. A major component
f the antitumor activity of alloBMT is immunologic
nd is mediated by donor T cells reacting against host
ntigens [1-3]. Perhaps the clearest evidence of immu-
ologic antitumor activity is the demonstration that do-
or lymphocyte infusions (DLIs) can induce remissions
n patients who relapse after alloBMT [4-8]. This is
urther supported by the ﬁnding that patients who
elapse after alloBMT can achieve remissions by with-
rawal of immunosuppression [9-11]. r
14The efﬁcacy of DLI is a function of the underlying
isease and disease status at the time of DLI. The best
esponses are seen in patients with chronic myeloid
eukemia (CML) in cytogenetic or chronic phase (CP)
elapse; durable remissions are achieved in 70% to 80%
f these patients, often at T-cell doses (1 107 CD3
cells per kilogram) that do not produce clinically
igniﬁcant graft-versus-host disease (GVHD) [6,12,13].
LI is less successful in other hematologic malignan-
ies, with response rates ranging from 10% in acute
ymphocytic leukemia (ALL) to as high as 40% in
ultiple myeloma (MM), myelodysplasia (MDS),
hronic lymphocytic leukemia, and indolent non-
odgkin lymphoma (NHL); however, many of theesponses are not durable [6,14-22].
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Graft-versus-Host Reactions and Effectiveness of DLI
BWe report a single-institution experience of DLI
n 83 consecutive patients with relapsed hematologic
alignancies over a 7-year period. We demonstrate
hat the percentage of donor chimerism at the time of
LI is a powerful predictor of response, as is the
evelopment of GVHD. Furthermore, patients who
chieved full donor chimerism after DLI were 22-fold
ore likely to achieve a complete remission (CR) than
atients with residual host cells present (P  .01).
lthough essential for achieving a CR, except in
ML, full donor chimerism was insufﬁcient to pre-
ent relapse.
ETHODS AND MATERIALS
All patients aged 18 years and older who received
LI(s) from an HLA-identical sibling after a myeloa-
lative allogeneic transplantation for a hematologic
alignancy at Johns Hopkins Hospital were included.
he treatment period extended from October 1995
hrough January 2003. DLI was given for relapsed
isease after alloBMT. Patients were eligible to re-
eive DLI if they had evidence of donor chimerism
5%) and were not being actively treated for
VHD. All patients gave informed consent for DLI
nd follow-up as approved by the Institutional Review
oard of the Johns Hopkins Hospital and University.
ollow-up on disease status and survival was com-
leted through October 2004. Complete follow-up
nformation was available on 77 patients. Patients with
evere GVHD and overwhelming infections were
onsidered deaths from GVHD.
esponse Criteria and Measurement of
onor/Host Chimerism
Responses were assessed by using standard re-
ponse criteria for each of the diseases being treated.
onor-host chimerism was determined by 1 of 3
ethods on peripheral blood and bone marrow sam-
les: the use of restriction fragment linked polymor-
hisms [23,24], polymerase chain reaction analysis of
ariable nucleotide tandem repeats [25,26], or by ﬂu-
rescence in situ hybridization using X and Y chro-
osome probes, if informative [27]. Pre-DLI chimer-
sm was measured within 4 weeks before the receipt of
LI. Post-DLI chimerism was measured 2 to 3 months
fter the administration of DLI.
raft-versus-Host Disease
Patients were evaluated using the Keystone stag-
ng system for acute GVHD and the International
one Marrow Transplantation Registry criteria for
hronic GVHD [28,29].
hemotherapy/Immune Adjuvants
Twenty-ﬁve patients received chemotherapy within
weeks before their DLI as part of a planned combina- G
B&MTion approach. These patients all had aggressive dis-
ase and were in need of cytoreduction to allow time
or development of an immunologic antitumor effect
rom DLI. In each case, DLI was given without as-
essing response to chemotherapy. Two patients re-
eived chemotherapy within the ﬁrst 4 weeks after
LI because of rapid disease progression. Two pa-
ients with CML received interferon alfa concomitant
ith their ﬁrst DLI, whereas interferon alfa or inter-
eukin 2 was given to 8 patients as an immune adjuvant
n the setting of DLI dose escalation.
onor Lymphocyte Infusions
Doses of DLI ranged from 0.1 to 5  108 CD3
cells per kilogram. Patients with CML in CP or
ytogenetic relapse received 0.1  108 CD3 T cells
er kilogram as their initial dose. The initial T-cell
oses for other patients ranged from 0.1 to 1.5  108
D3 T cells per kilogram. Patients with aggressive
iseases, relapsed acute leukemia, or aggressive lym-
homas (Hodgkin’s disease [HD] and diffuse large cell
DLC]) were given an initial T-cell dose of 1  108
D3 T cells per kilogram. Patients with myeloma or
DS/myeloproliferative disorder (MP) received 0.1
o 0.5  108 CD3 T cells per kilogram according to
he protocol they were enrolled on. Dose escalation
as used in patients who were alive and free of
VHD and who did not achieve a CR after the initial
ose of DLI or whose disease had clearly progressed at
east 3 months after the initial DLI. One patient with
LL was given escalated DLI at 2 months after the
nitial dose for evidence of disease progression. All
ther patients who received dose escalated DLI re-
eived it between 3 and 8 months after the initial DLI.
tatistical Methods
Statistical analysis was performed by using SPSS
1.0 (SPSS Inc., Chicago, IL), Stata (StataCorp, Col-
ege Station, TX), and SAS (SAS Institute, Cary, NC).
rogression-free survival was calculated for patients
ho achieved a remission, from the date of DLI to the
ate of disease progression or death from any cause.
verall survival was calculated from the date of DLI
o the date of death. Patients without evidence of
rogression were censored at the time of last contact.
ollow-up on disease status and survival was com-
leted through October 2004. Complete follow-up
nformation was available on 77 patients. The Fisher’s
xact test was used to compare binomial outcomes
etween groups. Kaplan-Meier methods were used to
alculate survival probability, and log-rank tests were
sed to test for differences in survival curves between
iagnostic groups. Cox proportional hazards models
nd 2 tests were used to determine which variables
ere associated with the onset and development of
VHD. These analyses were performed by using only
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4he ﬁrst DLI that each patient received so as not
onfound the interpretation by including the same
atient twice. Logistic regression models were also
sed to describe which characteristics were associated
ith a CR.
ESULTS
atient Characteristics
DLIs were given to 83 patients (Table 1) with
elapsed hematologic malignancies between October
995 and January 2003. Of these 83 patients, 64 received
infusion, and 19 received 2 infusions. The total
umber of DLIs given was 112. The median age was 45
ears (range, 21-67 years); 49 patients were men, and
4 were women.
DLI was given to 73 recipients of T cell–depleted
yeloablative allogeneic transplants and 7 recipients
f unmanipulated myeloablative allogeneic trans-
lants. Three patients received 2 myeloablative trans-
lants before DLI: 2 had a second alloBMT (1 T-cell
epleted [by elutriation] and 1 unmanipulated), and 1
eceived alloBMT for disease relapse after an autolo-
ous transplantation. DLI was given to treat the fol-
owing relapsed diseases: CML in CP or cytogenetic
able 1. Patient Characteristics
Variable Data
edian age, y (range) 45 (21-67)
ype of allogeneic transplantation
T-cell depleted 73
T-cell replete 7
Second allogeneic 2
Allogeneic after autologous 1
eason for DLI
Relapsed disease 83
CML in CP/cytogenetic relapse 17
CML in accelerated phase/blast crisis 5
Multiple myeloma 20
AML 13
MDS/MP 12
HD 8
Aggressive NHL 4
ALL 3
Follicular NHL 1
edian interval (d) between BMT and DLI
(range)
CML in CP (n  17) 916 (232-5339)
All other diseases (n  66) 427 (69-3702)
edian follow-up, d (range)
CML in CP (n  17) 857 (487-2657)
All other diseases (n  66) 383 (10-3031)
-cell dose (112 infusions) (T cells per
kilogram)
1  107 CD3 29
3-5  107 CD3 27
0.7-1.5  108 CD3 53
2-5  108 CD3 3
umber of T-cell infusions per patient (n  83)
One 64s
Two or more 19
16elapse (n 17), CML in accelerated phase/blast crisis
AP/BC; n  5), MM (n  20), acute myeloid leuke-
ia (AML; n  13), MDS/MP (n  12), HD (n  8),
ggressive NHL (n  4), ALL (n  3), and follicular
HL (n  1; Table 1).
The median interval between transplantation and
rst DLI was 492 days (range, 69-5339 days). For
atients with CML in CP or cytogenetic relapse, the
edian time to ﬁrst DLI was 916 days (range, 232-
339 days), which is signiﬁcantly longer than the me-
ian time to DLI for all other indications combined:
27 days (range, 69-3702 days; Table 1).
LI for Relapsed Disease
Salvage chemotherapy was given to 25 patients
ith relapsed disease, from 3 to 28 days before DLI.
he diseases treated included AML (n 7), HD (n 3),
M (n  5), MP (n  2), ALL (n  2), CML in
P/BC (n 2), MDS (n 2), aggressive NHL (n 1),
nd indolent NHL (n  1). The regimens varied and
ncluded cyclophosphamide, etoposide, topotecan,
ytarabine, and doxorubicin. In each case, the decision
o give chemotherapy was based on the aggressiveness
f the disease and the need to achieve cytoreduction to
llow time for development of an immunologic anti-
umor effect. Response to chemotherapy was not as-
essed before the administration of DLI because it was
planned combination approach. Of the 25 patients, 6
chieved CR, all after developing GVHD with DLI.
nly 2 of these 6 patients are alive in continuous CR;
patients subsequently died (2 of disease and 2 of
VHD in CR). Three patients achieved partial remis-
ions (PR), all with GVHD; 2 subsequently relapsed
nd died of their disease, and the other died of GVHD
ith an ongoing response.
As has been found in most series, patients with
ML in CP or cytogenetic relapse had the highest CR
ate, at 77% (Table 2), with a similar rate for both CP
nd cytogenetic relapse (Table 3). DLI also had sig-
iﬁcant activity in most other relapsed diseases, with
R rates of 50% in aggressive NHL, 33% in ALL,
6% in AML, 30% in MM, 20% in CML in AP/BC,
5% in MDS/MP, and 13% in HD (Table 2). With
he exception of CML in CP or cytogenetic relapse,
or which all responding patients except 1 (who died of
VHD) remain in CR, with a median follow-up of
57 days (range, 487-2657 days), relapses were com-
on in other diseases. Thus, of the 66 patients with
iseases other than CML in CP or cytogenetic re-
apse, only 14% (9/66) are alive in CR, with a median
ollow-up of 383 days (range, 10-3031 days) and a
edian survival of 321 days (range, 10-3031 days;
able 3). Although 31% of relapsed AML patients
emain in remission after DLI (median follow-up of
526 days; range, 1495-1551 days), the durable remis-
ion rate is 20% in all other diseases.
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Graft-versus-Host Reactions and Effectiveness of DLI
BAdditional dose-escalated DLI was given to 19
atients who did not achieve CR or had progression
ithin 3 months after the initial T-cell infusion. The
iseases treated included CML-CP (n 6), MDS/MP
n  5), MM (n  2), CML in AP (n  2), small
ymphocytic lymphoma (n  1), AML (n  1), ALL
n  1), and HD (n  1). Of the 6 CML patients in
P or cytogenetic relapse who received dose escala-
ion, 3 (50%) achieved CR. Of the 13 patients with
iseases other than CML in CP or cytogenetic re-
apse, only 1 (7%) achieved CR with dose escalation,
nd the CR was not durable despite the development
f GVHD.
raft-versus-Host Disease
The overall incidence of acute (grade II or
igher) or chronic GVHD was 36% after the ﬁrst
ose of DLI and was 43% when taking dose esca-
ation into consideration (Table 4). The overall
ncidence of acute GVHD (grade II or higher) was
5%. Chronic GVHD was seen in 33% of the
atients treated. The incidence of acute and chronic
VHD did not differ signiﬁcantly with the T-cell
ose given; it was 32%, 42%, 36%, and 33%, re-
able 2. DLI Outcomes
Variable In
esponse
CML in CP/cytogenetic relapse (n  17)
AML—relapsed (n  13)
All other relapsed diseases (n  53)
eaths (n  55)
Underlying disease
GVHD
Infection
Other (MI/interstitial pneumonitis/second malignancy)
I indicates myocardial infarction.
able 3. Disease-Speciﬁc Responses (n  83)
Diagnosis n
CR to
Initial
Dose
CR/PR
with Initial
Dose
CR to DLI
Including Dose
Escalation
C
In
ML 17 10 (59%) 10 (59%) 13 (77%)
Cyto 12 8 8 9
CP 5 2 2 4
ML (AP/BC) 5 1 (20%) 1 (20%) 1 (20%)
ML relapsed 13 6 (46%) 6 (46%) 6 (46%)
M 20 6 (30%) 8 (40%) 6 (30%)
DS/MP 12 2 (15%) 2 (15%) 2 (15%)
HL aggressive
relapsed 4 2 (50%) 3 (75%) 2 (50%)
D 8 1 (13%) 3 (38%) 1 (13%)
LL relapsed 3 0 (0%) 0 (0%) 1 (33%)
HL follicular 1 0 (0%) 0 (0%) 0 (0%)
LL indicates acute lymphocytic leukemia; AML, acute myeloid le
donor lymphocyte infusion; GVHD, graft-versus-host disease;
myeloma; MP, myeloproliferative disorder; NHL, non-Hodgkin
Cyto, cytogenetic relapse.
B&MTpectively, at CD3 T-cell doses of 1  107, 3 to 5
107, 0.7 to 1.5  108, and 5  108 cells per
ilogram. The median time to the development of
cute GVHD was 35 days (range, 12-159 days) and
o chronic GVHD was 85 days (range, 57-108 days)
fter DLI. Fatal GVHD was seen in 16% (13/83) of
he patients treated in this series.
auses of Death
To date, 55 (66%) of 83 patients have died. By far,
he most common cause of death was relapsed disease
60%; 33/55). GVHD caused or contributed to death
n 24% (13/55) of patients who died (5 in CR, 2 in PR,
nd 2 without measurable disease). Six patients died of
nfection (including 1 in CR and 1 in PR); 3 patients
ied of other causes (myocardial infarction, interstitial
neumonitis, and second malignancy). A Kaplan-Meier
urvival curve stratifying survival for patients with CML
n CP or cytogenetic relapse versus all other diseases is
hown in Figure 1, thus conﬁrming earlier ﬁndings that
emonstrated superior survival for patients with CML
n CP or cytogenetic relapse as compared with all
ther diseases (P  .001).
-Cell Dose Dose Escalation Alive in Continuous CR
(59%) 13/17 (77%) 12/17 (71%)
(46%) 6/13 (46%) 4/13 (31%)
(34%) 19/53 (36%) 5/53 (9%)
33
13
6
3
o DLI
Dose
tion
Relapse
after
DLI
Alive in
Continuous
CR
Death
(Disease,
GVHD, Other)
Median OS,
d (range)
7%) 0/13 12 (71%) 2 (1, 1, 0) NR (449-2657)
8 (67%)
4 (80%)
0%) 0/1 1 (20%) 4 (2, 0, 2) 1252 (10-2392)
6%) 2/6 4 (31%) 9 (4, 2, 3) 127 (15-1551)
0%) 2/8 3 (15%) 15 (11, 4, 0) 614 (25-3031)
5%) 0/2 0 10 (5, 2, 3) 210 (49-1027)
5%) 3/3 0 4 (2, 2, 0) 91 (91-1312)
8%) 2/3 1 (13%) 7 (6, 1, 0) 512 (475-1297)
3%) 1/1 0 3 (1, 1, 1) 34 (22-383)
%) 0/0 0 1 (1, 0, 0) N/A
; CML, chronic myeloid leukemia; CR, complete response; DLI,
odgkin disease; MDS, myelodysplastic syndrome; MM, multiple
oma; NR, not reached; OS, overall survival; PR, partial remission;itial T
10/17
6/13
18/53R/PR t
cluding
Escala
13 (7
9
4
1 (2
6 (4
8 (4
2 (1
3 (7
3 (3
1 (3
0 (0
ukemia
HD, H
lymph417
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4actors Predictive of GVHD and Response
By using a 2 test, patients with relapsed disease
ho developed grade II or higher acute or chronic
VHD were signiﬁcantly more likely to achieve a CR
han patients who did not (P  .001). When the
nalysis was repeated by looking at the CML in CP
ubgroup, the development of GVHD did not corre-
ate with achieving CR (P  .10), whereas the effect
ersisted in patients who received DLI for all other
able 4. GVHD According to T-Cell Infusion
Variable
Initial
T-Cell Dose
(n  83)
All Doses Including
Dose Escalation
(n  112 doses)
cute GVHD 26/83 (31%) 29/83 (35%)
Stage II 10 12
Stage III 5 5
Stage IV 11 12
hronic GVHD 21/83 (25%) 27/83 (33%)
Limited 5 4*
Extensive 16 23
Antecedent acute 17 20
cute or chronic GVHD 30/83 (36%) 36/83 (43%)
VHD indicates graft-versus-host disease.
One patient with limited-stage chronic GVHD developed exten-
sive chronic GVHD with dose escalation.
0 500 1000
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
S
ur
vi
va
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y
igure 1. Kaplan-Meier plot—overall survival after DLI (dashed li
ompares overall survival for patients with CML in CP or cytog
elationship between death and CML group was P  .001.
18elapsed diseases (P  .01). Univariable logistic re-
ression models were ﬁt to identify variables associ-
ted with a response to DLI (Table 5). In these mod-
ls, the only variable that was predictive of a response
as the reason for DLI; patients who received DLI for
ML in CP (cytogenetic relapse included with CP for
his analysis) were more likely to respond than pa-
ients who received DLI for relapsed disease other
han CML in CP. Univariable and multivariable lo-
istic regression models were ﬁt to describe the rela-
ionships among chimerism, GVHD, and response.
he percentage of donor chimerism before DLI had a
igniﬁcant effect on the development of GVHD and
ubsequent responses. Patients with50% donor chi-
erism before DLI were 4.5 times (95% conﬁdence
nterval, 1.7-12.5 times; P  .01) more likely to
chieve a CR than patients whose donor chimerism
as50% at the time of DLI (Table 5). Furthermore,
ccording to the Fisher t test, patients who achieved
ull donor chimerism were 21-fold more likely to
chieve a CR than patients with residual host cells
resent (P  .001). No other variable, including age,
atient/donor sex, time to DLI, or T-cell dose,
eached statistical signiﬁcance in these models when
he group was analyzed as a whole. When the sub-
2000 2500 3000
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All Others
CML: chronic phase/cytogenetic relapse
icate 95% conﬁdence intervals). This Kaplan-Meier survival curve
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Graft-versus-Host Reactions and Effectiveness of DLI
Broup of patients with AML was analyzed with the
ilcoxon rank test, the time between BMT and DLI
as statistically signiﬁcant: the median time was 544
ays (range, 203-1631 days) in the responders, com-
ared with 152 days (range, 69-420 days) in the non-
esponders (P  .035).
Cox proportional hazards models were used to
ook at factors associated with the development of
VHD (Table 6). Only the percentage of donor chi-
erism before DLI had a signiﬁcant effect on the
evelopment of GVHD. Patients with 50% donor
himerism before DLI were 3.4 times (hazard ratio,
.4; 95% conﬁdence interval, 1.5-7.6; P  .01) more
ikely to develop GVHD at any point in time than
atients whose donor chimerism was 50% at the
ime of DLI (Table 6).
echanisms Responsible for the Activity
f DLI in CML
CML is unique in its sensitivity to DLI in that
esponses are frequently seen in the absence of clini-
ally evident GVHD. The mechanisms responsible
or the responsiveness of CML to DLI, however,
emain unclear. Although most (17/19) of the CRs in
iseases other than CML were associated with clini-
ally apparent GVHD, 7 of the 13 CML patients (CP
nd cytogenetic) who achieved a CR to DLI exhibited
o evidence of GVHD. Of the 17 patients who re-
eived DLI for CML (in CP or cytogenetic relapse),
0 were part of a trial that used T-cell depletion
able 5. Univariate Logistic Regression Models Describing Variables
ssociated with CR Taking Only Initial DLI into Consideration (n  83)
Variable Odds Ratio P Value 95% CI
ge (y)
<35 1.4 .58 0.41-4.8
36-50 0.7 0.26-2.1
>50 — —
ex 0.95 .91 0.37-2.4
-cell dose
1  107 2.7 .17 0.94-8.1
3-5  107 1.4 0.41-4.7
>5  107 — —
ime from BMT
to DLI (d)
0-492 1.2 .70 0.48-3.0
>492 — —
eason for DLI
CML in CP 3.0 .05 1.00-9.0
Relapsed disease — —
onor chimerism
before DLI
0%-50% — — —
51%-100% 4.5 <.01 1.7-12.5
onor chimerism
after DLI
0%-50% — — —
51%-100% 16.5 <.01 5.3-51.2
I indicates conﬁdence interval.ollowed by granulocyte-macrophage colony-stimu- C
B&MTating factor for 2 months after BMT in an attempt to
revent relapse [30]. Granulocyte-macrophage colo-
y-stimulating factor has been shown to preferentially
erminally differentiate CML progenitors and was
hus added after transplantation in an effort to eradi-
ate residual CML cells that survived T cell–depleted
lloBMT [31-33]. Of the 23 patients who underwent
ransplantation on this trial, 8 exhibited stable mixed
himerism (10% host hematopoiesis; median, 18%;
ange, 11%-45%) without evidence of relapse (ab-
ence of Philadelphia chromosome by ﬂuorescent in
itu hybridization and cytogenetics; unpublished data).
lthough 2 of these 8 patients remain in remission
ith stable mixed chimerism at 2 and 3 years after
MT, 6 of 8 have subsequently relapsed and gone on
o receive DLI. All 6 cases achieved a complete cyto-
enetic and molecular remission with DLI. All 6 also
onverted to persistent full donor chimerism, al-
hough only 3 of the 6 developed any evidence of
VHD. Because normal and CML host hematopoi-
sis were both eliminated, the DLI responses in CML
ere associated with effective graft-versus-host reac-
ions, even when clinical GVHD was not apparent.
ISCUSSION
Most disease responses after DLI occur in the
etting of GVHD [6,15,34]. However, durable re-
able 6. Univariate Cox Proportional Hazards Models Were Fit
orrelating These Variables with the Onset and Development of
VHD, Taking Only Initial DLI into Consideration (n  83)
Variable Hazard Ratio P Value 95% CI
ge (y)
<35 0.42 .22 0.14-1.3
36-50 0.63 0.29-1.4
>50 — —
ex
Male to male 0.56 .50 0.23-1.4
Male to female 0.50 0.18-1.4
Female to male 0.58 0.18-1.9
Female to female — —
-cell dose
1  107 0.42 .11 0.17-1.1
3-5  107 1.0 0.44-2.3
>5  107 — —
ime from BMT to DLI (d)
0-492 0.65 .25 0.32-1.4
>492 —
onor chimerism before DLI
0%-50% — —
51%-100% 3.4 <.01 1.5-7.6
onor chimerism after DLI
0%-50% — —
51%-100% 1.9 .09 0.90-3.8
eason for DLI
CML in CP 0.64 .25 0.24-1.7
Relapsed disease — —
Time from BMT to DLI 1.00 0.99-1.0I indicates conﬁdence interval.
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4ponses are often seen in CP CML with T-cell doses
1  107 cells per kilogram) that are associated with a
ow incidence of clinically apparent GVHD [7,8,35].
e found that residual normal host hematopoiesis
as also eradicated in all CML patients who achieved
Rs with DLI. Thus, the CML patients who re-
ponded to DLI exhibited potent lymphohematopoi-
tic graft-versus-host reactions even though GVHD
as not clinically apparent in many patients. The
imilar sensitivity of CML and normal hematopoiesis
o DLI argues against a leukemia-speciﬁc immuno-
ogic reaction and probably explains CML’s high re-
ponse to DLI. With malignant progression to AP/
C, CML shows the same limited responsiveness to
LI as other hematologic malignancies.
Patients with 50% donor chimerism before DLI
ere more likely to achieve a CR. Furthermore, those
ho achieved full donor chimerism after DLI were 22
imes more likely to achieve a CR than patients who
id not. The ﬁnding that the degree of donor chimer-
sm correlates with disease response to DLI could be
xplained by donor chimerism serving as a marker of
inimal residual disease; that is, patients with high
evels of donor chimerism before DLI have the lowest
isease burdens at the time of DLI and thus might be
xpected to beneﬁt the most from DLI. However, the
egree of donor chimerism was also highly predictive
f the development of GVHD, and this ﬁnding should
ot be explained by donor chimerism being a marker
f disease burden. Because the development of GVHD
fter DLI was the strongest predictor of disease re-
ponse, the correlation between disease response to DLI
nd donor chimerism is likely a reﬂection of donor
himerism being amarker for graft-versus-host reactions
ather than disease burden.
Although necessary for the immunologic antitu-
or activity, GVHD produced signiﬁcant morbidity
nd mortality. GVHD was the cause of or contributed
o death in 24% of the patients who died. Recurrent
isease, however, was an even larger problem and led
o 60% of the deaths in this series. Moreover, only 2
f 25 patients who received chemotherapy for relapsed
isease before DLI are alive in continuous remission.
learly, outside of CML, novel approaches that en-
ance the antitumor activity of DLI while minimizing
VHD are needed. One approach that has shown
romise is the use of autologous tumor vaccines in
ombination with DLI in a murine model [36,37].
hus, it may be possible to incorporate tumor vac-
ines with DLI in an endeavor to educate donor T
ells and enhance antitumor activity, perhaps by using
ower doses of donor T cells that may reduce GVHD
38]. Even if this is effective, autologous tumor will
ot be available for all patients, and other approaches
ill be needed to improve the antitumor activity of
doptive immunotherapy.
20Dose escalation of DLI was used in 19 patients
ho did not respond or who relapsed after an initial
esponse to DLI and did not have active GVHD.
lthough dose escalation has been reported to induce
emissions in patients who do not respond [7,8], CML
as the only disease in which we saw durable re-
ponses with dose escalation. Of the 6 CML CP pa-
ients who received dose-escalated DLI, 3 achieved a
urable CR. As other groups have reported [6,13,15],
e found no correlation between the dose of T cells
dministered and the risk of developing GVHD.
DLIs clearly have the potential to induce remis-
ions in patients who relapse after allogeneic trans-
lantation. Their efﬁcacy seems greatest in patients
ith CML in CP or cytogenetic relapse, those with
50% donor chimerism at the time of DLI, and in
hose who develop GVHD and full donor chimerism
fter DLI. Unfortunately, except in CML, most pa-
ients continue to die of their underlying disease be-
ause of insufﬁcient antitumor activity even in the face
f active GVHD.
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